Tubulis’ next-generation antibody-drug conjugate (ADC) has been tied to an overall response rate (ORR) of 59% as the German ...
Europe’s leading cancer conference may be swimming in antibody-drug conjugate (ADC) data, but AstraZeneca remains convinced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback